Professor Gary Pisano of Harvard Business School once distilled the challenge of the biopharmaceutical industry to its essence: "The brutally simple problem is innovation," he wrote. "To add value, you have to find a way of making good drugs. Every other strategy is a sideshow." After more than 30 years at Eli Lilly and Co., I believe innovation is not only a great opportunity; it is an imperative. At this pivotal moment when some question whether companies like Lilly can continue to innovate amid the powerful headwinds of a challenging global health-care environment, I answer with a confident, "Yes!"
via indystar.com
How's Effient doin', John?
No comments:
Post a Comment